BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma (Nasdaq: BBIO) announced on May 8, 2026 that its compensation committee approved inducement equity grants for 52 new employees totaling 115,007 restricted stock units.

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced on May 8, 2026 that its compensation committee approved inducement equity grants for 52 new employees totaling 115,007 restricted stock units. One-quarter vests on May 16, 2027, then one‑twelfth of the remainder vests quarterly thereafter, subject to continued employment. Awards were granted under the company’s equity plan adopted November 2019 and amended February 10, 2023 and December 13, 2023, in compliance with Nasdaq Listing Rule 5635(c)(4).

Argus May 11 session

-4.02% close to close Open Argus

Details

News Market Reaction – BBIO

In the May 11 session, BBIO declined 4.02%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement RSU grants for 115,007 shares to 52 new employees under Nasdaq ...

Analysis

This announcement details inducement RSU grants for 115,007 shares to 52 new employees under Nasdaq Listing Rule 5635(c)(4), reflecting ongoing hiring and use of equity compensation. Context from recent filings shows Q1 2026 revenue of $194.5 million alongside a net loss of $164.0 million, and an effective $500,000,000 shelf and ATM program. Investors may monitor future equity issuance, cash trends, and clinical milestones when assessing the long-term impact.

Key Figures

Net revenue: $194.5 million Net product revenue: $180.6 million Net loss: $164.0 million +5 more

Net revenue

$194.5 million

Three months ended March 31, 2026 (10-Q)

Net product revenue

$180.6 million

Q1 2026 net product revenue (10-Q)

Net loss

$164.0 million

Net loss attributable to common stockholders, Q1 2026 (10-Q)

Operating cash outflow

$197.3 million

Operating cash outflow for Q1 2026 (10-Q)

Cash & cash equivalents

$879.9 million

Quarter-end balance as of March 31, 2026 (10-Q)

Convertible Senior Notes

$632.5 million

0.75% Convertible Senior Notes due 2033 issued (10-Q)

ATM / shelf capacity

$500,000,000

S-3ASR shelf and ATM equity distribution agreement

Inducement RSU shares

115,007 shares

Aggregate RSUs granted to 52 new employees under Nasdaq Rule 5635(c)(4)

Historical Context

5 past events · Latest: May 06

5 events

1. May 06

   Conference participation

   24h Move

   -0.9%

   Announced participation in multiple upcoming healthcare investor conferences.

2. May 06

   Regulatory approval

   24h Move

   -1.0%

   ANVISA approval for BEYONTTRA (acoramidis) to treat ATTR-CM in Brazil.

3. May 05

   Clinical data update

   24h Move

   -0.3%

   Planned presentation of primary Phase 3 CALIBRATE results for encaleret at ECE.

4. May 04

   Clinical data update

   24h Move

   +0.6%

   New Phase 3 ATTRibute-CM acoramidis data to be presented at ESC-Heart Failure.

5. Apr 30

   Earnings date notice

   24h Move

   +0.2%

   Announced timing of Q1 2026 financial results and commercial updates call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, Nasdaq Listing Rule 5635(c)(4)

2 terms

restricted stock units financial

"approved equity grants to 52 new employees in restricted stock units for an aggregate..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Nasdaq Listing Rule 5635(c)(4) regulatory

"inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)..."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on May 6, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 52 new employees in restricted stock units for an aggregate of 115,007 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on May 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio (BBIO) announce on May 8, 2026 about new-hire stock grants?

BridgeBio granted 115,007 restricted stock units to 52 new hires. According to the company, these awards were approved May 6, 2026 as inducement grants under Nasdaq Listing Rule 5635(c)(4). Vesting is tied to continued employment and schedule details follow below.

How does the vesting schedule work for BridgeBio's (BBIO) May 2026 inducement RSUs?

One-quarter of each RSU grant vests on May 16, 2027. According to the company, the remaining shares vest in equal one‑twelfth portions on a quarterly basis thereafter, subject to continued employment with BridgeBio or its subsidiaries.

Will BridgeBio (BBIO) use an existing equity plan for the May 2026 inducement grants?

Yes. According to the company, the awards were granted pursuant to the terms of its equity plan adopted in November 2019 and amended February 10, 2023 and December 13, 2023. The grants were executed under that plan's provisions.

Do BridgeBio's (BBIO) inducement grants require ongoing employment to vest?

Yes. According to the company, vesting of the restricted stock units is conditioned on each employee's continued employment with BridgeBio or a subsidiary on each vesting date, per the stated vesting schedule and plan terms.

Are BridgeBio's (BBIO) May 2026 inducement grants related to Nasdaq Listing Rule 5635(c)(4)?

Yes. According to the company, the awards were each granted as inducement material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4), and were approved by the compensation committee on May 6, 2026.